CN101467039B - 散乱蛋白pdz调节剂 - Google Patents

散乱蛋白pdz调节剂 Download PDF

Info

Publication number
CN101467039B
CN101467039B CN2007800216108A CN200780021610A CN101467039B CN 101467039 B CN101467039 B CN 101467039B CN 2007800216108 A CN2007800216108 A CN 2007800216108A CN 200780021610 A CN200780021610 A CN 200780021610A CN 101467039 B CN101467039 B CN 101467039B
Authority
CN
China
Prior art keywords
polypeptide
peptide
dvl
pdz
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800216108A
Other languages
English (en)
Chinese (zh)
Other versions
CN101467039A (zh
Inventor
迈克·科斯塔
萨克德夫·S·西德休
张映楠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to CN201310261484.0A priority Critical patent/CN103351425B/zh
Publication of CN101467039A publication Critical patent/CN101467039A/zh
Application granted granted Critical
Publication of CN101467039B publication Critical patent/CN101467039B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Image Processing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2007800216108A 2006-04-10 2007-04-09 散乱蛋白pdz调节剂 Expired - Fee Related CN101467039B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310261484.0A CN103351425B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79067306P 2006-04-10 2006-04-10
US60/790,673 2006-04-10
PCT/US2007/066267 WO2007121147A2 (en) 2006-04-10 2007-04-09 Disheveled pdz modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310261484.0A Division CN103351425B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂

Publications (2)

Publication Number Publication Date
CN101467039A CN101467039A (zh) 2009-06-24
CN101467039B true CN101467039B (zh) 2013-11-06

Family

ID=38537937

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800216108A Expired - Fee Related CN101467039B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂
CN201310261484.0A Expired - Fee Related CN103351425B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310261484.0A Expired - Fee Related CN103351425B (zh) 2006-04-10 2007-04-09 散乱蛋白pdz调节剂

Country Status (8)

Country Link
US (2) US7695928B2 (cg-RX-API-DMAC7.html)
EP (2) EP2343551B1 (cg-RX-API-DMAC7.html)
JP (1) JP5290148B2 (cg-RX-API-DMAC7.html)
CN (2) CN101467039B (cg-RX-API-DMAC7.html)
AU (1) AU2007238186B2 (cg-RX-API-DMAC7.html)
CA (1) CA2648322C (cg-RX-API-DMAC7.html)
ES (2) ES2385261T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007121147A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
KR101278073B1 (ko) * 2008-08-04 2013-06-24 연세대학교 산학협력단 Ｉｄｂｆ의 신규 용도
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
MX366804B (es) 2012-02-11 2019-07-25 Genentech Inc Translocaciones de la r-espondina y sus metodos de uso.
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220901D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
US9520180B1 (en) 2014-03-11 2016-12-13 Hypres, Inc. System and method for cryogenic hybrid technology computing and memory
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0134986A2 (de) * 1983-07-13 1985-03-27 FARMITALIA CARLO ERBA S.r.l. Biologisch aktive Heptapeptide, Mittel, die diese enthalten und Anwendungsverfahren
EP0183245A2 (en) * 1984-11-30 1986-06-04 FARMITALIA CARLO ERBA S.r.l. Animal growth promotant
WO2002090544A2 (en) * 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
US20030148264A1 (en) * 2001-07-06 2003-08-07 Genentech, Inc. Phage displayed PDZ domain ligands

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5688936A (en) * 1992-06-11 1997-11-18 The Regents Of The University Of California Vesicle membrane transport proteins
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
DK0779806T3 (da) 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
CN1102854C (zh) 1995-06-07 2003-03-12 阿尔克姆斯控制治疗公司 人生长激素的延续释放组合物
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
JP2002522029A (ja) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド コートタンパク質の改変によるファージ提示における改良した形質転換効率
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
CA2501235A1 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
CA2572469A1 (en) * 2004-07-01 2006-01-19 The Regents Of The University Of California Small molecule inhibition of a pdz-domain interaction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0134986A2 (de) * 1983-07-13 1985-03-27 FARMITALIA CARLO ERBA S.r.l. Biologisch aktive Heptapeptide, Mittel, die diese enthalten und Anwendungsverfahren
EP0183245A2 (en) * 1984-11-30 1986-06-04 FARMITALIA CARLO ERBA S.r.l. Animal growth promotant
WO2002090544A2 (en) * 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
US20030148264A1 (en) * 2001-07-06 2003-08-07 Genentech, Inc. Phage displayed PDZ domain ligands

Also Published As

Publication number Publication date
AU2007238186A1 (en) 2007-10-25
EP2343551B1 (en) 2014-05-28
CA2648322C (en) 2017-11-28
US20100136580A1 (en) 2010-06-03
ES2487637T3 (es) 2014-08-22
HK1131438A1 (en) 2010-01-22
CN103351425B (zh) 2016-01-20
WO2007121147A2 (en) 2007-10-25
JP5290148B2 (ja) 2013-09-18
EP2343551A1 (en) 2011-07-13
CA2648322A1 (en) 2007-10-25
CN103351425A (zh) 2013-10-16
JP2009533465A (ja) 2009-09-17
US7977064B2 (en) 2011-07-12
EP2002259A2 (en) 2008-12-17
AU2007238186B2 (en) 2014-01-09
US20080167386A1 (en) 2008-07-10
EP2002259B1 (en) 2012-05-16
US7695928B2 (en) 2010-04-13
WO2007121147A3 (en) 2008-01-10
ES2385261T3 (es) 2012-07-20
CN101467039A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
CN101467039B (zh) 散乱蛋白pdz调节剂
Conradi et al. An RGD helper sequence in CagL of Helicobacter pylori assists in interactions with integrins and injection of CagA
US20080089862A1 (en) Protease inhibitors and method of screening thereof
CN109328067A (zh) 诱导程序性细胞死亡的cd47激动剂、及其治疗程序性细胞死亡缺陷相关疾病的用途
JP2013544798A (ja) Ｗｎｔ経路を調節する方法および組成物
TW200846358A (en) HtrA1-PDZ and HtrA3-PDZ modulators
JP2022023215A (ja) Ｄｐｅｐ－１結合組成物および使用の方法
AU2005269639A1 (en) Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
WO2011071280A2 (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
JP2022509258A (ja) Ｄｐｅｐ－１結合剤および使用の方法
US20130190254A1 (en) Polypeptides that bind membrane proteins
US20210171589A1 (en) Truncated cartilage-homing peptides and peptide complexes and methods of use thereof
Kenngott et al. Identification of targeting peptides for mucosal delivery in sheep and mice
US6703482B2 (en) Src SH3 binding peptides and methods of isolating and using same
CN109266731A (zh) Tim-3与NF90的相互作用在预防或治疗病毒感染产品中的应用
CN101848933A (zh) Trpc结构域和sestd1结构域的复合物及涉及所述复合物的方法和用途
US20050266498A1 (en) Method for screening biomolecule activity regulator
HK1131438B (en) Disheveled pdz modulators
Schachter Characterizing Notch1 Singaling Regulation And Amyloid Beta Cleavage
KR20130103301A (ko) 전사인자에 특이적으로 결합하는 ｔｆ-ｂｐｂ
Lian Development and Optimization of Protein-Protein Interaction Inhibitors by Combinatorial and Medicinal Chemistry
PINTO FUNCTIONAL STUDIES OF THE DEUBIQUITINATING ENZYMES USP19, USP4 AND UCH-L1
Starkey Template Based Design of Anti-Metastatic Drugs from the Active Conformation of Laminin Peptide II

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131438

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131438

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131106

Termination date: 20190409